FDA Encourages Pediatric Master Protocols With Bayesian Approach

27 Sep 2016

• By Michael Cipriano

Most trials currently use of frequentist statistics, but agency argues that Bayesian methods allow for better extrapolation.

Could drugmakers begin to more frequently explore the Bayesian approach into data extrapolation for pediatric product development?

The model was highly touted by FDA speakers at a Sept. 23 public workshop on pediatric master protocols cohosted by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Already a subscriber?